Chemotherapy News and Research

Latest Chemotherapy News and Research

Treating advanced cervical cancer: an interview with Dr. Krishnansu Tewari

Cervical cancer affects approximately 500,000 women every year globally of which 250,000 die annually, making it the 2nd leading cause of cancer-related death in women.

9 Apr 2014

Research shows blocking DNA repair improves radiation therapy for glioblastomas

UT Southwestern Medical Center researchers have demonstrated in both cancer cell lines and in mice that blocking critical DNA repair mechanisms could improve the effectiveness of radiation therapy for highly fatal brain tumors called glioblastomas.

9 Apr 2014

Study: Cetuximab drug used in combination with chemotherapy to treat advanced colorectal cancer is not effective

Research from the University of Southampton has shown a drug, used in combination with chemotherapy to treat advanced colorectal cancer, is not effective in some settings, and indeed may result in more rapid cancer progression.

9 Apr 2014

Researchers receive NIH grant for pediatric acute myelogenous leukemia treatment

A $1.92 million grant from the National Institutes of Health (NIH) was awarded to a research team that focuses on new approaches for treatment of relapsed pediatric acute myelogenous leukemia (rAML), led by Yang Liu, PhD, Bothworth Chair and Director of the Center for Cancer and Immunology Research (CCIR) at Children's Research Institute of Children's National Health System, and Reuven Schore, MD, member of CCIR and attending physician in the Leukemia & Lymphoma Program of the Division of Oncology of the Center for Cancer and Blood Disorders.

9 Apr 2014

Researchers identify novel compound effective against drug-resistant lung cancer

Despite advances made in detecting and treating nonsmall cell lung cancer, its prognosis remains grim. Even patients whose cancers are caught at their earliest stage have only a 50 percent chance of five-year survival. This poor prognosis is due in part to the cancer's ability to resist treatment, rendering the chemotherapy ineffective.

9 Apr 2014

Production of Immutep’s ImmuFact IMP321 starts at WuXi AppTec facilities in China

Immutep S.A., the biopharmaceutical company specializing in immuno-oncology, and Eddingpharm have started production of Immutep’s ImmuFact IMP321 (a LAG-3Ig fusion protein) at WuXi AppTec facilities in China. The product is being produced to European, U.S. and Chinese GMP standards.

8 Apr 2014

Access provides update on new formulation of anti-inflammatory drug amlexanox

ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP) provided an update on a new formulation of the anti-inflammatory drug amlexanox, called LexaGard™, for the treatment of inflammatory and ulcerative conditions of the esophagus.

8 Apr 2014

Prostate cancer breakthroughs offer new hope for men

Men have lower life expectancy than women. This discrepancy is especially pronounced for African American men who live 6 fewer years than women. According to the CDC, life expectancy in the US is 76 years for men compared to 81 for women.

8 Apr 2014

Ambit initiates QUANTUM-R Phase 3 clinical trial of quizartinib in FLT3-ITD positive AML patients

Ambit Biosciences, a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, today announced the initiation of the QUANTUM-R Phase 3 clinical trial comparing quizartinib as monotherapy to chemotherapy regimens in relapsed/refractory acute myeloid leukemia (AML) patients with the FMS-like tyrosine kinase-3 (FLT3)-ITD mutation.

8 Apr 2014

DelMar presents pre-clinical study data that evaluates activity of VAL-083 in drug-resistant NSCLC

DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar") today announced the presentation of new data in a poster entitled, "In vivo efficacy of VAL-083 in the treatment of non-small cell lung cancer." DelMar's data was presented on Sunday, April 6, 2014 during the Novel Cytotoxic Strategies Session at the 105th Annual Meeting of the American Association for Cancer Research (AACR) in San Diego.

8 Apr 2014

SU2C and Farrah Fawcett announce formation of research team dedicated to HPV-related cancers

Stand Up To Cancer (SU2C) and the Farrah Fawcett Foundation, along with the American Association for Cancer Research (AACR), SU2C's Scientific Partner, announced the formation of a research team dedicated to HPV-related cancers during a press event today at the AACR Annual Meeting 2014, held here April 5-9.

8 Apr 2014

Bezos family gifts $20M to Fred Hutchinson scientists for development of novel cancer immunotherapies

Fred Hutchinson Cancer Research Center scientists striving for new cancer cures - and the patients who stand to benefit from them - got an enormous boost today when the Bezos family committed $20 million to support the development of novel cancer immunotherapies. It is the largest single contribution in Fred Hutch's history.

8 Apr 2014

Combination therapy with MEK and BRAF inhibitors for anaplastic thyroid cancer proves effective

Researchers from the Jacks Laboratory at MIT's Koch Institute for Integrative Cancer Research (KI) have developed and characterized a genetically engineered mouse that successfully models progression from papillary thyroid cancer, which has an excellent prognosis, to anaplastic thyroid cancer (ATC), a highly lethal disease.

8 Apr 2014

I-SPY 2 trial qualifies neratinib for HER2-positive breast cancer

In an innovative clinical trial led by UC San Francisco, the experimental drug neratinib along with standard chemotherapy was found to be a beneficial treatment for some women with newly diagnosed, high-risk breast cancer.

8 Apr 2014

Dream team aims to turn pancreatic cancer into treatable disease

UC San Francisco has been selected to join a national "dream team" on pancreatic cancer, part of a project designed to accelerate treatment and discoveries for one of the most deadly forms of cancer.

8 Apr 2014

Magnetic nanoparticle (mNP) hyperthermia in breast cancer treatment

In a presentation exploring the promise of magnetic nanoparticle (mNP) hyperthermia in breast cancer treatment, Dartmouth researcher P. Jack Hoopes, DMV, PhD, reviewed preclinical studies conducted at Norris Cotton Cancer Center and discuss plans for early-phase clinical studies in humans at the annual meeting of the American Association for Cancer Research (AACR).

8 Apr 2014

Researchers identify potential treatment targets for incurable form of pediatric brain cancer

Researchers from the University of Toronto's Department of Laboratory Medicine and Pathobiology (LMP) have defined potential treatment targets for a previously incurable form of pediatric brain cancer called Diffuse Intrinsic Pontine Glioma (DIPG).

8 Apr 2014

Genome Project offers new leads to improve outcomes for children with high-grade glioma brain tumors

The St. Jude Children's Research Hospital-Washington University Pediatric Cancer Genome Project has identified new mutations in pediatric brain tumors known as high-grade gliomas (HGGs), which most often occur in the youngest patients.

8 Apr 2014

Ambit initiates Phase 2 study of quizartinib in acute myeloid leukemia patients

Ambit Biosciences, a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, today announced the initiation of the Phase 2 cohort of the MD Anderson Cancer Center-sponsored Phase 1/2 study of quizartinib in combination with either 5-azacitidine or low dose cytarabine for previously untreated FLT3-ITD positive acute myeloid leukemia (AML) patients age 60 or older, or FLT3-ITD positive AML patients 18 years of age or older in first relapse.

7 Apr 2014

Merck KGaA initiates Phase 3 START2 study of MUC1 antigen-specific cancer immunotherapy tecemotide

Oncothyreon Inc. today announced that Merck KGaA, Darmstadt, Germany, has initiated the international Phase 3 START2 study, which is designed to assess the efficacy and safety of the investigational MUC1 antigen-specific cancer immunotherapy tecemotide (also known as L-BLP25) in patients with unresectable, locally advanced Stage III non-small cell lung cancer (NSCLC).

7 Apr 2014

Chemotherapy News and Research

Latest Chemotherapy News and Research

Treating advanced cervical cancer: an interview with Dr. Krishnansu Tewari

Research shows blocking DNA repair improves radiation therapy for glioblastomas

Study: Cetuximab drug used in combination with chemotherapy to treat advanced colorectal cancer is not effective

Researchers receive NIH grant for pediatric acute myelogenous leukemia treatment

Researchers identify novel compound effective against drug-resistant lung cancer

Production of Immutep’s ImmuFact IMP321 starts at WuXi AppTec facilities in China

Access provides update on new formulation of anti-inflammatory drug amlexanox

Prostate cancer breakthroughs offer new hope for men

Ambit initiates QUANTUM-R Phase 3 clinical trial of quizartinib in FLT3-ITD positive AML patients

DelMar presents pre-clinical study data that evaluates activity of VAL-083 in drug-resistant NSCLC

SU2C and Farrah Fawcett announce formation of research team dedicated to HPV-related cancers

Bezos family gifts $20M to Fred Hutchinson scientists for development of novel cancer immunotherapies

Combination therapy with MEK and BRAF inhibitors for anaplastic thyroid cancer proves effective

I-SPY 2 trial qualifies neratinib for HER2-positive breast cancer

Dream team aims to turn pancreatic cancer into treatable disease

Magnetic nanoparticle (mNP) hyperthermia in breast cancer treatment

Researchers identify potential treatment targets for incurable form of pediatric brain cancer

Genome Project offers new leads to improve outcomes for children with high-grade glioma brain tumors

Ambit initiates Phase 2 study of quizartinib in acute myeloid leukemia patients

Merck KGaA initiates Phase 3 START2 study of MUC1 antigen-specific cancer immunotherapy tecemotide

Cancer Research - Second Edition eBook

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Chemotherapy News and Research

Latest Chemotherapy News and Research

Cancer Research - Second Edition eBook

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Newsletters you may be interested in